ESLA - NASDAQ
Estrella Immunopharma, Inc.
$1.17
+0.41%Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
At a Glance
Live Snapshotesla
Cash at Beginning of Period
Last Annual Value
916.92K
3-Year CAGR
24%
5-Year CAGR
%
10-Year CAGR
%
Estrella Immunopharma, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Estrella Immunopharma, Inc. NASDAQ:ESLA | 916.92K | -28.2% | N/A | N/A | |
 Instil Bio, Inc. NASDAQ:TIL | 10.63M | -37.6% | -46.5% | N/A | |
 Tevogen Bio Holdings Inc. NASDAQ:TVGN | 1.05M | -42.3% | 207.3% | N/A | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | 4.09M | -32.8% | -32.2% | N/A | |
 BeyondSpring Inc. NASDAQ:BYSI | 16.05M | -22.4% | -31.9% | 4.0% | |
 Cue Biopharma, Inc. NASDAQ:CUE | 22.61M | -24.1% | -21.3% | 13.4% | |
 MiNK Therapeutics, Inc. NASDAQ:INKT | 4.58B | 515.4% | 342.7% | N/A | |
 MediciNova, Inc. NASDAQ:MNOV | 40.36M | 29.7% | -7.6% | 6.2% | |
 OS Therapies Incorporated NYSE:OSTX | 38.98K | -39.0% | -49.9% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 14927.54B | 9402.5% | 1541.2% | 318.4% | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 3.86M | -10.6% | 9.1% | -7.6% |
Estrella Immunopharma, Inc. Fair Value Envelope
Related Guides
Continue your ESLA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.